Abstract

The androgen-receptor pathway inhibitors (ARPI) are standard treatment of metastatic castration-resistant prostate cancer (mCRPC). However, the mechanisms of both primary and acquired resistance remain largely unknown.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call